

1 **Efficacy and Safety of Fezolinetant in Moderate-to-Severe Vasomotor Symptoms**  
2 **Associated With Menopause: A Phase 3 RCT**

3  
4 **Authors**

5 Kimball A. Johnson, MD,<sup>1</sup> Nancy Martin, MD, PharmD,<sup>2</sup> Rossella E. Nappi, MD, PhD,<sup>3</sup> Genevieve Neal-  
6 Perry, MD, PhD,<sup>4</sup> Marla Shapiro, CM, MDCM,<sup>5</sup> Petra Stute, MD,<sup>6</sup> Rebecca C. Thurston, PhD,<sup>7</sup> Wendy  
7 Wolfman, MD,<sup>5</sup> Marci English, MPH,<sup>8</sup> Catherine Franklin, BS,<sup>2</sup> Misun Lee, PhD,<sup>8</sup> Nanette Santoro, MD<sup>9</sup>

8  
9 **Author Affiliations**

10 <sup>1</sup>iResearch Atlanta, LLC, Decatur, Georgia, USA

11 <sup>2</sup>Employee of Astellas Pharma Global Development at the time of the study

12 <sup>3</sup>University of Pavia, Fondazione Policlinico IRCCS S. Matteo, Pavia, Italy

13 <sup>4</sup>UNC School of Medicine, Chapel Hill, NC, USA

14 <sup>5</sup>University of Toronto, Toronto, Ontario, Canada

15 <sup>6</sup>Inselspital, Bern, Switzerland

16 <sup>7</sup>University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

17 <sup>8</sup>stellas Pharma Global Development, Inc., Northbrook, IL, USA

18 <sup>9</sup>University of Colorado School of Medicine, Aurora, CO, USA

19  
20 **Email Addresses**

21 Kimball A. Johnson: [drjohnson@iresearchatlanta.com](mailto:drjohnson@iresearchatlanta.com); Nancy Martin: [algranati@yahoo.com](mailto:algranati@yahoo.com); Rossella E.

22 Nappi: [renappi@tin.it](mailto:renappi@tin.it); Genevieve Neal-Perry: [genevieve\\_nealperry@med.unc.edu](mailto:genevieve_nealperry@med.unc.edu); Marla Shapiro:

23 [MarlaMD@aol.com](mailto:MarlaMD@aol.com); Petra Stute: [petra.stute@insel.ch](mailto:petra.stute@insel.ch); Rebecca C. Thurston: [thurstonrc@upmc.edu](mailto:thurstonrc@upmc.edu);

24 Wendy Wolfman: [Wendy.Wolfman@sinaihealth.ca](mailto:Wendy.Wolfman@sinaihealth.ca); Marci English: [marci.english@astellas.com](mailto:marci.english@astellas.com);

1 Catherine Franklin: frankca48@yahoo.com; Misun Lee: [misun.lee@astellas.com](mailto:misun.lee@astellas.com); Nanette Santoro:  
2 [Nanette.santoro@cuanschutz.edu](mailto:Nanette.santoro@cuanschutz.edu)

3

4 **Corresponding Author**

5 Nanette Santoro, MD

6 Address: University of Colorado School of Medicine

7 Fitzsimons Building

8 13001 East 17th Place

9 Aurora, CO 80045

10 Email: [Nanette.santoro@cuanschutz.edu](mailto:Nanette.santoro@cuanschutz.edu)

11 Telephone: 303-724-2041

12 Fax: 303-724-2061

13 ORCID ID: 0000-0001-9096-7490

14

15 **Disclosures:** KJ is a study investigator and consultant for Astellas and a study investigator for iResearch  
16 Atlanta, LLC. ME, and ML are employees of Astellas Pharma Inc. NM and CF were employees of  
17 Astellas Pharma Inc at the time of the study. REN had past financial relationships (lecturer, member of  
18 advisory boards, and/or consultant) with Boehringer Ingelheim, Eli Lilly, Endoceutics, Gedeon Richter,  
19 HRA Pharma, Merck Sharpe & Dohme, Novo Nordisk, Palatin Technologies, Pfizer, Procter & Gamble,  
20 Teva Women's Health and Zambon; ongoing relationships with Abbott, Astellas, Bayer HealthCare,  
21 Exeltis, Fidia, Gedeon Richter, HRA Pharma, Organon, Shionogi and Theramex; serves as General  
22 Secretary of the International Menopause Society. GN-P is a member of the scientific advisory board for  
23 Astellas and Ferring Pharmaceuticals, and has received research funding from Merck and NICHD. She is  
24 also Vice President of Diversity, Equity and Structural Change for the Society for Gynecological  
25 Investigations, is on the Programing Committee Chair for the American Society of Reproductive

1 Medicine, holds Committee Membership of the Endocrine Society, and is an Associate Editor for the  
2 *Journal of Clinical Endocrinology and Metabolism*. MS, CM is on the advisory board for and receives  
3 consulting fees or honoraria from Aspen, Astellas, Bayer, BioSyent, Duchesnay, GlaxoSmithKline,  
4 Merck, Mithra, Pfizer, Searchlight, Sprout, Sunovion, and Therapeutics MD, and fulfills a leadership or  
5 fiduciary role for the International Menopause Society, the Terry Fox Research Institute and Research  
6 Canada. PS is a consultant for Astellas, a board member for DMG and EMAS, and President of the  
7 SGEM. RCT is a consultant and advisor for Astellas, a consultant for Bayer Healthcare, Hello  
8 Therapeutics, and Happify Health, and a past consultant for Pfizer, Procter and Gamble, and Vira Health.  
9 She serves on the Board of Trustees for the North American Menopause Society. WW is on the advisory  
10 board and consultant/speaker for Astellas, BioSyent, Knight, Merck, Pfizer, and Searchlight. She is the  
11 President of the Canadian Menopause Society. NS is a study investigator and consultant for Astellas, a  
12 member of the scientific advisory board for Amazon (Project Ember), MenoGeniX, and is a consultant for  
13 Ansh Labs and QUE Oncology. She is on the Board of Directors for the North American Menopause  
14 Society, and is Past President of the Society for Reproductive Investigations.

15  
16 Abstract word count: 250

17 Body word count: 4271

18 References: 42

19 Figures/Tables:(5 Figures, 7 Tables)

20 NCT04003142

21  
22 Short title of 50 or fewer characters for page headings: Fezolinetant for treatment of menopausal VMS  
23  
24  
25

1 **Abstract**

2 **Context:** Vasomotor symptoms (VMS) are common, bothersome, and can persist for years before and  
3 after menopause.

4 **Objective:** We aimed to assess efficacy/safety of fezolinetant for treatment of moderate-to-severe VMS  
5 associated with menopause.

6 **Methods:** In this double-blind, placebo-controlled, 12-week (W) phase 3 trial with a 40W active  
7 treatment extension (NCT04003142; SKYLIGHT 2) women aged 40–65 years with minimum average 7  
8 moderate-to-severe VMS/day were randomized to 12 weeks' once-daily placebo, fezolinetant 30 mg, or  
9 fezolinetant 45 mg. Completers were rerandomized to fezolinetant 30/45 mg for 40 additional weeks.  
10 Coprimary efficacy endpoints were mean daily change from baseline to W4 and W12 in VMS frequency  
11 and severity. Safety was also assessed.

12 **Results** Both fezolinetant doses statistically significantly reduced VMS frequency/severity at W4 and  
13 W12 vs placebo. For VMS frequency, W4 least squares mean (SE) reduction vs placebo: fezolinetant 30  
14 mg,  $-1.82$  (0.46;  $P < .001$ ); 45 mg,  $-2.55$  (0.46;  $P < .001$ ); W12: 30 mg,  $-1.86$  (0.55;  $P < .001$ ); 45 mg,  $-$   
15  $2.53$  (0.55;  $P < .001$ ). For VMS severity, W4: 30 mg,  $-0.15$  (0.06;  $P < .05$ ); 45 mg,  $-0.29$  (0.06;  $P < .001$ );  
16 W12: 30 mg,  $-0.16$  (0.08;  $P < .05$ ); 45 mg,  $-0.29$  (0.08;  $P < .001$ ). Improvement in VMS frequency and  
17 severity was observed by W1; maintained through W52. Serious TEAEs were infrequent; these were  
18 reported by 2%, 1%, and 0% of those receiving fezolinetant 30 mg, fezolinetant 45 mg, and placebo,  
19 respectively.

20 **Conclusions** Daily fezolinetant 30 mg and 45 mg were efficacious and well-tolerated for treating  
21 moderate-to-severe VMS associated with menopause.

22  
23 **Keywords:** fezolinetant, vasomotor symptoms, neurokinin 3 receptor antagonist, KNDy, nonhormonal

## 1 INTRODUCTION

2 Vasomotor symptoms (VMS), characterized by hot flashes, affect a large proportion of women during  
3 menopausal transition (1-7). Up to 80% of perimenopausal women in the Study of Women's Health  
4 Across the Nation reported VMS during the previous 2 weeks when surveyed on an annual basis (7). The  
5 International Collaboration for a Life Course Approach to Reproductive Health and Chronic Disease  
6 Events study, examining data from 10 countries, found VMS prevalence in women in their late 50s to be  
7 30% to 50% (8). In a cross-sectional study of Australian women aged 65–79 years, 33% reported VMS  
8 (9). Persisting for a median duration of 7.4 years (10), VMS can significantly affect sleep and quality of  
9 life (QoL), lead to fatigue and mood changes, and affect work and relationships (11-15).

10 Hormone therapy (HT) with combined estrogen and progestogen (or estrogen alone) is an  
11 effective choice for VMS management. However, it is not appropriate for every woman, depending on  
12 underlying medical condition and risk factors, age, time since menopause, or preference (16,17).  
13 Therefore, safe, effective, targeted nonhormonal therapy for relief of VMS associated with menopause is  
14 desirable, particularly for women primarily suffering from VMS and unable or unwilling to take HT.

15 The thermoregulatory center in the brain hypothalamus is innervated by  
16 kisspeptin/neurokinin B/dynorphin (KNDy) neurons. These neurons are stimulated by the  
17 neuropeptide neurokinin B, acting at the neurokinin 3 receptors, and inhibited by estrogen. With  
18 declining estrogen levels during the menopausal transition, neurokinin 3 receptor-mediated  
19 activation is unopposed, leading to hypertrophy of the KNDy neurons, and altered activity on the  
20 thermoregulatory center. The thermoregulatory center triggers heat dissipation effectors.

21 Vasodilation in the skin causes heat loss, which is experienced as hot flashes, sweating, and  
22 chills (18) (4,19,20). Fezolinetant, in development for potential treatment of moderate-to-severe VMS  
23 associated with menopause, is a nonhormonal selective neurokinin-3 receptor (NK3R) antagonist that  
24 blocks NKB binding on the KNDy neuron, restoring normal sensitivity of the thermoregulatory center  
25 (21-23). Its molecular structure and mechanism of action have been described previously (19)

1 Results from phase 2 trials have demonstrated rapid and substantial reduction in VMS frequency  
2 and severity, translating into improvements in health-related QoL (21,22,24). The clinical development  
3 program for fezolinetant comprises several trials that investigate efficacy and safety of this novel  
4 nonhormonal NK3R antagonist. SKYLIGHT 1 (NCT04003155) and SKYLIGHT 2 (NCT04003142)  
5 investigate efficacy and safety and are 12-week randomized, placebo-controlled trials of fezolinetant 30  
6 mg/day and 45 mg/day followed by a 40-week active treatment extension period. SKYLIGHT 4  
7 (NCT04003389) focuses on long-term safety and tolerability of fezolinetant 30 mg/day and 45 mg/day in  
8 a randomized, placebo-controlled 52-week study. In this manuscript, we focus on the efficacy and safety  
9 outcomes from SKYLIGHT 2.

## 11 METHODS

12 SKYLIGHT 2 was conducted in accordance with Declaration of Helsinki, Good Clinical Practice, and  
13 International Council for Harmonisation guidelines. An independent ethics committee or institutional  
14 review board reviewed ethical, scientific, and medical appropriateness of the study at each site before data  
15 collection. Written informed consent was obtained from all participants before any study-related  
16 procedures.

### 18 Study Design

19 This was a multinational, randomized, double-blind, placebo-controlled, multicenter, phase 3 trial in  
20 women aged 40–65 years and confirmed as menopausal, with a minimum average of 7 moderate-to-  
21 severe VMS/day, who were seeking treatment or relief for VMS. All women had one of the following:  
22 spontaneous amenorrhea for  $\geq 12$  consecutive months, spontaneous amenorrhea for  $\geq 6$  months with  
23 biochemical criteria of menopause (follicle stimulating hormone  $> 40$  IU/l), or bilateral oophorectomy  $\geq 6$   
24 weeks before the screening visit (with or without hysterectomy). Full inclusion and exclusion criteria are  
25 presented in Table 1. Demographic data (age, race, sex, height, weight, and smoking status) were  
26 collected at screening. The study design is shown in Fig. 1.

1 The study was conducted at 146 sites in 7 countries (United States, Canada, Czechia, Latvia,  
2 Poland, Spain, United Kingdom) between July 2019 and April 2021. Participants were randomized 1:1:1  
3 to placebo, fezolinetant 30 mg, or fezolinetant 45 mg for 12 weeks. Randomization was double-blind, and  
4 the randomization number was assigned based on information obtained from Interactive Response  
5 Technology (Cenduit Ltd, Nottingham, UK), which was used to stratify participants by smoking status  
6 (active smoker or non-smoker [former/never]). The investigators, project team members, clinical staff,  
7 and participants were blinded to which treatment was administered. Participants took 2 tablets orally once  
8 daily with placebo and active tablets being indistinguishable in appearance and shape (those on  
9 fezolinetant 30 mg received one 30-mg tablet and one 15-mg placebo tablet, those on 45 mg received one  
10 15-mg tablet and one 30-mg tablet, those on placebo received 2 placebo tablets [one 30-mg placebo tablet  
11 and one 15-mg placebo tablet] to match). After completing 12 weeks of treatment, participants on placebo  
12 were rerandomized in a blinded fashion to fezolinetant 30 mg or 45 mg, whereas women initially  
13 randomized to either fezolinetant arm continued on their assigned dose for an additional 40 weeks of  
14 treatment in an extension period.

## 16 **Efficacy Assessments**

17 The primary objective was to evaluate the efficacy of fezolinetant vs placebo on the frequency and  
18 severity of moderate-to-severe VMS. Coprimary endpoints were mean change in daily frequency of  
19 moderate-to-severe VMS from baseline to weeks 4 and 12 and mean change in daily severity of  
20 moderate-to-severe VMS from baseline to weeks 4 and 12. Daily VMS data were collected using an  
21 electronic VMS diary, completed daily during a 24-hour period by participants from screening through to  
22 the follow-up visit. The VMS diary is an interactive, electronic data capture system available for data  
23 entry 24 h/day. Women were provided with a reference guide within the diary, which included  
24 definitions: mild: sensation of heat without sweating; moderate: sensation of heat with sweating, able to  
25 continue activity; and severe: sensation of heat with sweating, causing cessation of activity (25).

1           The key secondary endpoint was mean change in the Patient-Reported Outcomes Measurement  
2 Information System Sleep Disturbance – Short Form 8b (PROMIS SD SF 8b) total score from baseline to  
3 week 12. PROMIS SD SF 8b assesses self-reported sleep disturbance during the prior 7 days and includes  
4 perceptions of restless sleep; satisfaction with sleep; refreshing sleep; difficulties sleeping, getting to  
5 sleep, or staying asleep; amount of sleep; and sleep quality (26). Responses to the 8 items range from 1–5,  
6 and the range of possible summed raw scores is 8–40. Higher scores on PROMIS SD SF 8b indicate more  
7 disturbed sleep. Participants completed PROMIS SD SF 8b electronically via a tablet at each site, without  
8 assistance. Other secondary endpoints included mean change in daily frequency and severity of moderate  
9 and severe VMS from baseline to each week to week 12. Percentage reductions of at least 50% and 75%  
10 in frequency of moderate and severe VMS from baseline were also analyzed each week to week 12.

11           Exploratory endpoints were Patient Global Impression of Change in Sleep Disturbance (PGI-C  
12 SD), mean change from baseline on Patient Global Impression of Severity in Sleep Disturbance (PGI-S  
13 SD), and mean change in Menopause-Specific Quality of Life (MENQOL) total score. The PGI-C SD  
14 PRO outcomes measure asked women to rate how well they were sleeping at that time compared with the  
15 start of the study using a scale ranging from (1) much better to (7) much worse. The PGI-S SD asked  
16 women to rate the severity of any current problems while sleeping at night using a scale from (1) no  
17 problems to (4) severe problems. The MENQOL is a 29-item patient-reported outcome measure assessing  
18 the impact of 4 domains of menopausal symptoms (vasomotor, psychosocial, physical, and sexual) during  
19 the prior week. Specific symptoms are rated as present or not present, and if present rated on a scale of (0)  
20 not bothersome to (6) extremely bothersome.

21           Efficacy data (VMS, PROMIS SD SF 8b, PGI-C SD, PGI-S SD and MENQOL) were collected for  
22 up to 52 weeks to assess persistence of effect and were summarized descriptively, with no inferential  
23 testing as there was no placebo control.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

## Safety Assessments

Safety was assessed by frequency of treatment-emergent adverse events (TEAEs) throughout the study. Adverse events (AEs) were coded using the Medical Dictionary for Regulatory Activities (MedDRA) v23.0 and summarized by System Organ Class and Preferred Term. Clinical laboratory tests were performed at screening and all visits and included hematology and biochemistry, including liver safety assessments (alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase, total bilirubin). Endometrial biopsy was performed if there was any uterine bleeding, if the participant discontinued from the study, and at the end of the extension period.

## Statistical Analyses

The sample size estimate was 450 women (150 in each treatment arm). A sample size of 450 provided at least 79% power to detect a treatment difference in mean daily frequency of 2 episodes (assuming a SD of 5), to detect a treatment difference in mean severity of 0.4 (assuming a SD of 1), and providing about 95% power to detect a difference of 4.3 from placebo on the key secondary endpoint of the PROMIS SD SF 8b (assuming a SD of 7).

Continuous data were summarized with descriptive statistics (number of participants, mean, SD, minimum, median, maximum). Categorical data were summarized with frequencies and percentages. The efficacy analyses used the full analysis set (FAS) comprising all randomized participants who received  $\geq 1$  dose of study drug. A sensitivity analysis was also carried out for the coprimarily efficacy endpoints based on the per protocol set. The safety analysis set (SAF) also consisted of all randomized participants who received  $\geq 1$  dose of study drug. Since all participants took the dose they were assigned, the FAS and SAF were identical, comprising all randomized participants who received at least 1 dose of study drug.

All statistical comparisons were conducted using two-sided tests at the  $\alpha = 0.05$  significance level. For each of the 4 coprimarily efficacy endpoints, a mixed model repeated measures (MMRM) analysis of covariance was used with treatment group, week, and smoking status (current vs former or

1 never) as factors, and baseline weight and baseline measurement as covariates, as well as an interaction of  
2 treatment by week and of baseline measurement by week. The family-wise type I error rate for comparing  
3 the 2 fezolinetant dose groups with placebo for the 4 coprimary efficacy endpoints was controlled using a  
4 Hochberg approach. All 4 coprimary endpoints had to be statistically significant for a given dose to be  
5 considered successful and the largest  $P$  value in each dose group was used because it represented the least  
6 significant of the coprimary endpoints. If all coprimary endpoints were statistically significant  
7 (fezolinetant at both doses vs placebo), the 5% alpha from the coprimary endpoint analyses passed to  
8 testing the key secondary endpoint as part of the family-wise error rate. An unstructured covariance  
9 structure shared across treatment groups was used to model the within-patient errors. The Kenward-Roger  
10 approximation was used to estimate maximum likelihood-based repeated measures approach. The  
11 treatment difference was estimated at all study weeks. The MMRM used all available on-treatment data to  
12 inform mean treatment effect estimates without requiring explicit imputation for missing data (ie,  
13 discontinued participants). This approach is consistent with the hypothetical strategy used for the  
14 estimand (a treatment effect to be estimated as if post-randomization events that may preclude  
15 observation of the primary endpoints have not occurred), which is to compare participants as though they  
16 had continued the assigned treatment. Generally, the mechanism of missing data was assumed to be  
17 missing at random. There was no explicit imputation of missing data for the primary analysis. A  
18 sensitivity analysis (Jump to Reference) was conducted to confirm that the data from participants who  
19 discontinued the study were missing at random.

20 Comparisons between the fezolinetant and placebo groups were calculated based on least squares  
21 means. The daily mean frequency and severity per week (eg, week 4 and week 12) were calculated as the  
22 average frequency and severity over non-missing days from 7 days. PROMIS SD SF 8b and MENQOL  
23 total score (key secondary endpoints) were analyzed using an MMRM, similar to the primary analysis of  
24 the coprimary endpoints, with spatial power as the back-up covariance structure. The PGI-C SD and PGI-  
25 S SD were analyzed using the Cochran-Mantel-Haenszel test with modified ridit scores.

26

## 1 RESULTS

### 2 Study Population

3 In total, 501 women were randomized and 500 were included in the SAF and FAS, as 1 woman did not  
4 take the study drug (placebo, n = 167; fezolinetant 30 mg, n = 166; fezolinetant 45 mg, n = 167; Fig. 2).

5 In both the double-blind and extension parts of the study, all treatment groups were similar with respect to  
6 demographics and baseline characteristics (Table 2).

### 8 Efficacy Endpoints

9 Both fezolinetant doses met statistical significance in reducing VMS frequency and severity/24 h at weeks  
10 4 and 12 vs placebo with multiplicity adjustment (Table 3). Results were mirrored in the per-protocol set  
11 (data not shown). For fezolinetant 30 mg, mean (SD) daily VMS frequency was reduced from 11.23  
12 (4.88) at baseline to 5.79 (6.02) at week 4 and 4.80 (5.59) at week 12. For fezolinetant 45 mg, mean (SD)  
13 daily VMS was reduced from 11.79 (8.26) at baseline to 5.67 (7.29) at week 4 and 4.49 (5.39) at week 12.  
14 In comparison, for placebo, mean (SD) daily VMS frequency was reduced from 11.59 (5.02) at baseline  
15 to 8.08 (6.50) at week 4 and 6.73 (7.58) at week 12. This equated to a mean percentage change of –  
16 51.60% for fezolinetant 30 mg and –55.16% for fezolinetant 45 mg at week 4, vs –33.60% for placebo. At  
17 week 12, mean percentage changes were –58.64% for fezolinetant 30 mg and –64.27% for fezolinetant 45  
18 mg, vs –45.35% for placebo.

19 In addition to the differences observed at weeks 4 and 12 (coprimary endpoints), the difference vs  
20 placebo was statistically significant for fezolinetant 45 mg at all timepoints between weeks 1 and 12 for  
21 both VMS frequency and severity (without multiplicity analysis); fezolinetant 30 mg showed statistically  
22 significant differences vs placebo at all weeks for VMS frequency. When women were rerandomized to  
23 either fezolinetant 30 mg or 45 mg, a rapid reduction was observed in VMS frequency and severity; this  
24 was observed as early as week 1 of treatment and was maintained throughout the 12-week placebo-  
25 controlled period (Fig. 3). Persistence of efficacy for all fezolinetant groups was observed during the 40-  
26 week active treatment extension period.

1 Both fezolinetant doses reduced PROMIS SD SF 8b total score vs placebo at week 12 (secondary  
2 endpoint) and week 4 (Table 4). Improvement at week 12 was statistically significant for fezolinetant 45  
3 mg (least squares [LS] mean [SE] difference,  $-2.0$  [0.7]; 95% CI,  $-3.5$  to  $-0.6$ ;  $P = .007$ ), but not for  
4 fezolinetant 30 mg (LS mean [SE] difference,  $-0.7$  [0.7]; 95% CI,  $-2.1$  to  $0.8$ ;  $P = .381$ ). Improvement in  
5 PROMIS SD SF 8b total score was also maintained throughout the extension period. Exploratory analyses  
6 of sleep showed that the proportion of participants who reported moderately better and much better PGI-C  
7 SD at week 12 was higher in both fezolinetant groups (all  $P < 0.05$ ) vs placebo (Fig. 4A). There was also  
8 a difference in the proportions of participants reporting sleep disturbance severity problems in the  
9 fezolinetant 30 mg and 45 mg groups vs placebo at week 12 (Fig. 4B).

10 Percentages of participants achieving at least 50% reductions in VMS frequency by week 12 were  
11 50.6% and 60.5% in the fezolinetant 30-mg and 45-mg groups, respectively, vs 42.5% in the placebo  
12 group (Fig. 5). Improvements from baseline in MENQOL total score were observed at weeks 4 and 12 in  
13 participants treated with fezolinetant 30 mg and 45 mg vs placebo ( $P \leq 0.002$  for fezolinetant 45 mg at  
14 weeks 4 and 12 and for fezolinetant 30 mg at week 12; Table 5). Similar results were seen for the other  
15 secondary endpoints (data not shown).

## 17 **Safety**

18 During the 12-week double-blind period, TEAEs were reported by 40% (fezolinetant 30 mg), 36%  
19 (fezolinetant 45 mg), and 32% (placebo) of women (Table 6). Headache was the most common TEAE in  
20 fezolinetant groups during the double-blind period (3% [fezolinetant 30 mg], 4% [fezolinetant 45 mg],  
21 2% [placebo]). Serious TEAEs were infrequent; these were reported by 2%, 1%, and 0% of those  
22 receiving fezolinetant 30 mg, fezolinetant 45 mg, and placebo, respectively. There were no serious drug-  
23 related TEAEs. TEAEs leading to discontinuation were non-serious and were reported by 1%, 3%, and  
24 1% of those receiving fezolinetant 30 mg, fezolinetant 45 mg, and placebo, respectively. These were  
25 fatigue and oropharyngeal pain in 1 participant and alexithymia in 1 participant in the fezolinetant 30 mg

1 group, arthralgia in 1 participant; abdominal pain, hematochezia, nausea, vomiting, and colitis in 1  
2 participant; international normalized ratio increased in 1 participant; nausea in 1 participant; and alanine  
3 aminotransferase increased in 1 participant in the fezolinetant 45 mg group: and increased appetite and  
4 hot flash in 1 participant in the placebo group.

5 Overall, elevations in liver transaminases were asymptomatic and infrequent (Table 7). Of 500  
6 participants receiving study drug, 6 participants had ALT values more than 3 times upper limit of normal  
7 (ULN) across treatment groups (2 [fezolinetant 30 mg], 3 [fezolinetant 45 mg], 1 [placebo]). One woman  
8 receiving fezolinetant 30 mg had an ALT result more than 5 times ULN during the double-blind period.  
9 AST values more than 3 times ULN occurred in 1 fezolinetant 30 mg participant and 1 placebo  
10 participant. Increases in ALT or AST were generally asymptomatic; isolated, intermittent or transient, and  
11 generally returned to baseline while on treatment or discontinuation. Of the 5 participants on fezolinetant  
12 with ALT or AST >3 x ULN during the 12-week placebo-controlled phase, levels returned to within the  
13 normal range on treatment in 2 participants, with treatment interruption in 2 participants, and after  
14 treatment discontinuation in 1 participant. Importantly, there were no reported cases of Hy's law (ALT or  
15 AST > 3 × ULN and bilirubin > 2 × ULN with no other reason to explain the combination), an indicator  
16 of drug-induced liver injury (27). No new safety signals were observed in the 40-week active treatment  
17 extension period that were not evident in the 12-week placebo-controlled period.

### 18 19 **Extension Study Efficacy and Safety**

20 Baseline demographics at the start of the 40-week active treatment extension period are shown in Table 2.  
21 A total of 166 women continued to receive fezolinetant 30 mg; 167 continued to receive fezolinetant 45  
22 mg; 76 were re-randomized from placebo to fezolinetant 30 mg; and 75 were re-randomized from placebo  
23 to fezolinetant 45 mg. Fezolinetant efficacy persisted throughout the study as shown by the change in  
24 VMS frequency and severity over time (Fig. 3) and change in sleep disturbance at weeks 24 and 52  
25 (Table 4).

1 At least 1 AE was experienced by 56.6% of the participants in the placebo/fezolinetant 30-mg  
2 group, 60.0% in the placebo/fezolinetant 45-mg group, 64.5% in the fezolinetant 30-mg group, and 63.5%  
3 in the fezolinetant 45-mg group (Table 6). The incidence of AEs by preferred term was balanced across  
4 the placebo/fezolinetant 30-mg and 45-mg and fezolinetant 30-mg and 45-mg groups. COVID-19 and  
5 headache were the most commonly reported AE; again there were no cases consistent with Hy's law  
6 (Table 7). One participant in the placebo/fezolinetant 45-mg group died due to multiple injuries from a  
7 motorcycle passenger accident; this event was considered by the investigator as not related to study  
8 intervention.

## 9 10 **DISCUSSION**

11 Herein we demonstrate that fezolinetant, a novel nonhormonal treatment for VMS, is effective and safe in  
12 reducing this cardinal symptom of menopause by over 50% from baseline. The study successfully met the  
13 4 coprimary efficacy endpoints. Both doses demonstrated statistically significant improvements vs  
14 placebo in mean daily VMS frequency and severity at weeks 4 and 12. These results suggest that  
15 fezolinetant is efficacious for treatment of moderate-to-severe VMS at daily doses of 30 mg and 45 mg.  
16 Efficacy of fezolinetant was seen within the first week of treatment and was maintained through week 12,  
17 with a daily reduction of 2 to 3 VMS episodes from baseline to week 12 compared with placebo. Efficacy  
18 was persistent and reductions in VMS frequency were maintained during the 40-week extension period, at  
19 levels consistent with the results of the initial 12 weeks. These results confirm those of phase 2 trials  
20 (21,22), which showed significant reductions in total VMS score (22), and mean frequency of moderate-  
21 to-severe VMS (21), and significant improvements in QoL measures at week 12 vs placebo (21). At week  
22 12, the LS mean reduction in VMS frequency was greater than 50% in both fezolinetant groups, and a  
23 50% reduction is considered clinically significant (28). Additionally, persistence of efficacy was observed  
24 during the 52-week treatment period.

25 The statistically significant reduction in VMS frequency and severity during the 12-week period  
26 translated into clinically meaningful improvements in QoL as measured by the MENQOL, a menopause-

1 specific patient-reported outcome tool. Improvement in the MENQOL total score suggests that both  
2 fezolinetant doses significantly improved QoL from as early as week 4 of the study. When taken together,  
3 the replicate designed SKYLIGHT 1 and SKYLIGHT 2 studies provide data on the efficacy of  
4 fezolinetant in more than 1000 women. Data from SKYLIGHT 2 confirm those from SKYLIGHT 1 (29)  
5 and provide further evidence of the potential of fezolinetant as a novel nonhormonal therapeutic option  
6 for moderate-to-severe VMS.

7         Although the study did not require sleep disturbance as an entry requirement, both fezolinetant  
8 doses demonstrated numerical improvements in sleep (PROMIS SD SF 8b total score; key secondary  
9 endpoint), reaching statistical significance for the 45-mg dose and maintained through the 40-week  
10 extension period. This is noteworthy because nearly half of postmenopausal women report sleep  
11 impairment, and VMS is associated with poor sleep quality, nighttime awakenings (30), and excessive  
12 daytime sleepiness (31). Night sweats commonly result in sleep interruptions and difficulty returning to  
13 sleep (32). The magnitude of sleep relief is large compared with paroxetine, which was effective at  
14 reducing VMS frequency but had no clinically significant benefit on sleep parameters (33); but this is  
15 limited by being reported in only two studies. In contrast, fezolinetant 30 mg did not achieve a  
16 statistically significant effect on sleep in the current study. This difference most likely reflects a dose  
17 effect. Additionally, reduction in VMS alone may improve sleep, so further investigation is warranted. In  
18 the phase 2a trial, fezolinetant improved sleep quality, measured using the Leeds Sleep Evaluation  
19 Questionnaire, at all test intervals (22). Patient-reported data in the current study show that a higher  
20 proportion of women receiving fezolinetant reported a positive change in PGI-C SD at weeks 4 and 12  
21 and a decrease in the proportion of those with severe sleep problems at weeks 4 and 12 compared with  
22 those receiving placebo. Reduction in sleep disturbance may offer a clinical benefit by improved  
23 functioning and quality of life, and may potentially reduce the risk of short- and longer-term  
24 consequences of sleep deprivation (34).

1 Through week 12, there was a low incidence of serious AEs, no serious drug-related AEs, and a  
2 generally unremarkable safety profile for fezolinetant at both doses. A total of 6 participants across all  
3 treatment groups had ALT/AST elevations more than 3 times ULN (2 [fezolinetant 30 mg], 3  
4 [fezolinetant 45 mg], 1 [placebo]). These results support the hepatic safety of fezolinetant, with no cases  
5 of Hy's law to suggest drug-induced liver injury. Increases in ALT/AST were generally asymptomatic;  
6 isolated, intermittent or transient, and generally returned to baseline while on treatment or after  
7 discontinuation. No elevations were associated with evidence of liver function impairment (increased  
8 bilirubin or International Normalized Ratio) or liver-associated clinical symptoms. Although favorable,  
9 limited conclusions can be drawn from the 12-week short-term safety data. Data from 52 weeks of study,  
10 while not placebo-controlled after 12 weeks, affirm that the safety findings and the overall safety data in  
11 SKYLIGHT 2 were similar to those observed in SKYLIGHT 1 (35). Additional data on the long-term  
12 safety of fezolinetant are anticipated from SKYLIGHT 4 (NCT04003389), the 52-week double-blind,  
13 placebo-controlled safety study in approximately 1830 women seeking treatment for VMS associated  
14 with menopause.

15 Reductions in VMS frequency and severity in this study were also seen in the placebo group,  
16 replicating the well-documented placebo effect in studies investigating potential treatments for VMS  
17 (36,37). Previous studies have reported that treatment of menopausal women with placebo alone reduced  
18 hot flash frequency by 33% (38). SKYLIGHT 2 was designed to conform to the U.S. Food and Drug  
19 Administration (FDA) Draft Guidance on clinical studies of VMS, with a placebo group and requirement  
20 for four coprimary endpoints (40). Despite the placebo effect, statistically significant differences were  
21 observed for both fezolinetant doses versus placebo at weeks 4 and 12 and continued during the extension  
22 period.

23 A limitation of this study is absence of placebo beyond 12 weeks, although inclusion of placebo  
24 for long periods is difficult from a patient perspective. Additionally, other menopause symptoms, such as  
25 mood changes and sexual function were not assessed.



1 HT is considered a standard of care for menopausal symptoms, although may not be suitable for,  
2 or preferred by, all women. Currently, nonhormonal treatments include selective serotonin reuptake  
3 inhibitors, serotonin and norepinephrine reuptake inhibitors, clonidine, gabapentin, oxybutynin (41) and  
4 paroxetine, the only nonhormonal therapy approved by the FDA for VMS (42). NK3R antagonists offer a  
5 new selective therapeutic approach and various candidates have been advanced into clinical development  
6 (19). Fezolinetant is under development as a nonhormonal treatment option for moderate-to-severe VMS  
7 associated with menopause.

8 In summary, fezolinetant 30 mg and 45 mg once daily demonstrated efficacy and were well  
9 tolerated for treatment of moderate-to-severe VMS associated with menopause. There was a rapid onset  
10 of effect by week 1, with a full effect by week 4 that was sustained through 52 weeks with a daily  
11 reduction of 2 to 3 VMS episodes more than placebo from baseline to week 12 for fezolinetant groups. In  
12 addition, fezolinetant 45 mg significantly improved patient-reported sleep. These findings support  
13 continued development of fezolinetant as a novel nonhormonal treatment option for VMS associated with  
14 menopause.

## 15 **Acknowledgements**

17 The authors would like to thank the study investigators and staff and all women with moderate-to-severe  
18 VMS who took part in the study. Medical writing support was provided by Sue Cooper CMPP of  
19 Envision Scientific Solutions, Horsham, UK, and funded by Astellas Pharma Inc. Written permission has  
20 been obtained to include this individual in the acknowledgments. All medications used in this study were  
21 prepared by Astellas Pharma Inc. Packaging and labeling was by Fisher Basel.

## 22 **Funding**

23 This study was sponsored by Astellas Pharma Inc.  
24  
25

## 1 **Author Contributions**

2 KJ was the coordinating investigator for the study and NS, RCT, GN-P, PS, MS, and AC were Scientific  
3 Steering Committee members. NM, ML, CF, and ME contributed to the concept and design of the study.  
4 ML was responsible for the statistical analyses. All authors had access to the study data, were involved in  
5 the analysis and interpretation of the data, take responsibility for the accuracy of the analysis, and had  
6 authority over manuscript preparation and the decision to submit the manuscript for publication. All  
7 authors approve the manuscript for submission.

## 9 **Additional Information**

10 **Correspondence:** Nanette Santoro, MD, University of Colorado School of Medicine, Fitzsimons  
11 Building, 13001 East 17th Place, Aurora, CO 80045. Email: [Nanette.santoro@cuanschutz.edu](mailto:Nanette.santoro@cuanschutz.edu).  
12 Telephone: 303-724-2041. Fax: 303-724-2061

13  
14  
15 **Data Availability:** Researchers may request access to anonymized participant-level data, trial-level data  
16 and protocols from Astellas sponsored clinical trials at [www.clinicalstudydatarequest.com](http://www.clinicalstudydatarequest.com). For the  
17 Astellas criteria on data sharing, see: [https://clinicalstudydatarequest.com/Study-Sponsors/Study-](https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Astellas.aspx)  
18 [Sponsors-Astellas.aspx](https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Astellas.aspx).

## 20 **Previous Presentation**

21 The results from the 12-week part of the SKYLIGHT 2 study were presented at the 32nd North American  
22 Menopause Society (NAMS) Annual Meeting; September 22-25, 2021; Washington, DC (late-breaking  
23 abstract: Johnson K, Lademacher C, Nappi RE, et al. A phase 3, randomized, placebo-controlled, 12-  
24 week, double-blind study, plus a non-controlled extension treatment period, to assess efficacy and safety  
25 of fezolinetant, a neurokinin-3 receptor antagonist, in women with moderate-to-severe vasomotor  
26 symptoms associated with menopause. Abstract available at: *Menopause*. 2021;28(12):1438-1476). These  
27 data were also presented at the 14th Congress of the European Society of Gynecology; November 10-13,

1 2021; Venice, Italy (Johnson K, Nappi RE, Neal-Perry G, et al. A phase 3, randomized, placebo-  
2 controlled, 12-week, double-blind study, plus a non-controlled extension treatment period, to assess  
3 efficacy and safety of fezolinetant, a neurokinin-3 receptor antagonist, in women with moderate-to-severe  
4 vasomotor symptoms associated with menopause. Abstract available at: *European Gynecology &*  
5 *Obstetrics*. 2021;3(Supplement 1):75:OP03). An abstract featuring results from the 52-week study has  
6 been accepted by the  
7 Annual Meeting and Expo of the Endocrine Society (ENDO) for presentation at the 33<sup>rd</sup> Annual Meeting  
8 in Atlanta, Georgia, USA; June 11-14, 2022.

## 10 REFERENCES

- 11 1. Dacks PA, Krajewski SJ, Rance NE. Activation of neurokinin 3 receptors in the median preoptic  
12 nucleus decreases core temperature in the rat. *Endocrinology*. 2011;152(12):4894-4905.
- 13 2. Padilla SL, Johnson CW, Barker FD, Patterson MA, Palmiter RD. A neural circuit underlying the  
14 generation of hot flushes. *Cell Rep*. 2018;24(2):271-277.
- 15 3. Mittelman-Smith MA, Williams H, Krajewski-Hall SJ, McMullen NT, Rance NE. Role for  
16 kisspeptin/neurokinin B/dynorphin (KNDy) neurons in cutaneous vasodilatation and the estrogen  
17 modulation of body temperature. *Proc Natl Acad Sci U S A*. 2012;109(48):19846-19851.
- 18 4. Rance NE, Dacks PA, Mittelman-Smith MA, Romanovsky AA, Krajewski-Hall SJ. Modulation  
19 of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and  
20 dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. *Front Neuroendocrinol*.  
21 2013;34(3):211-227.
- 22 5. Dacks PA, Rance NE. Effects of estradiol on the thermoneutral zone and core temperature in  
23 ovariectomized rats. *Endocrinology*. 2010;151(3):1187-1193.

- 1 6. Krajewski-Hall SJ, Miranda Dos Santos F, McMullen NT, Blackmore EM, Rance NE.  
2 Glutamatergic neurokinin 3 receptor neurons in the median preoptic nucleus modulate heat-  
3 defense pathways in female mice. *Endocrinology*. 2019;160(4):803-816.
- 4 7. Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, Sternfeld B, Matthews K.  
5 Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across  
6 the menopausal transition: study of women's health across the nation. *Am J Public Health*.  
7 2006;96(7):1226-1235.
- 8 8. Mishra GD, Chung H-F, Pandeya N, Dobson AJ, Jones L, Avis NE, Crawford SL, Gold EB,  
9 Brown D, Sievert LL, Brunner E, Cade JE, Burley VJ, Greenwood DC, Giles GG, Bruinsma F,  
10 Goodman A, Hayashi K, Lee JS, Mizunuma H, Kuh D, Cooper R, Hardy R, Obermeyer CM, Lee  
11 KA, Simonsen MK, Yoshizawa T, Woods NF, Mitchell ES, Hamer M, Demakakos P, Sandin S,  
12 Adami HO, Weiderpass E, Anderson D. The InterLACE study: design, data harmonization and  
13 characteristics across 20 studies on women's health. *Maturitas*. 2016;92:176-185.
- 14 9. Zeleke BM, Bell RJ, Billah B, Davis SR. Vasomotor and sexual symptoms in older Australian  
15 women: a cross-sectional study. *Fertil Steril*. 2016;105(1):149-155.e141.
- 16 10. Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, Hess R, Joffe  
17 H, Kravitz HM, Tepper PG, Thurston RC. Duration of menopausal vasomotor symptoms over the  
18 menopause transition. *JAMA Intern Med*. 2015;175(4):531-539.
- 19 11. Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of  
20 Women's Health across the Nation. *Obstet Gynecol Clin North Am*. 2011;38(3):489-501.
- 21 12. Whiteley J, DiBonaventura M, Wagner JS, Alvir J, Shah S. The impact of menopausal symptoms  
22 on quality of life, productivity, and economic outcomes. *J Womens Health (Larchmt)*.  
23 2013;22(11):983-990.

- 1 13. Williams RE, Levine KB, Kalilani L, Lewis J, Clark RV. Menopause-specific questionnaire  
2 assessment in US population-based study shows negative impact on health-related quality of life.  
3 *Maturitas*. 2009;62(2):153-159.
- 4 14. Worsley R, Bell RJ, Gartoulla P, Robinson PJ, Davis SR. Moderate-severe vasomotor symptoms  
5 are associated with moderate-severe depressive symptoms. *J Womens Health (Larchmt)*.  
6 2017;26(7):712-718.
- 7 15. Nappi RE, Kroll R, Siddiqui E, Stoykova B, Rea C, Gemmen E, Schultz NM. Global cross-  
8 sectional survey of women with vasomotor symptoms associated with menopause: prevalence  
9 and quality of life burden. *Menopause*. 2021;28(8):875-882.
- 10 16. The NAMS Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy  
11 position statement of The North American Menopause Society. *Menopause*. 2017;24(7):728-753.
- 12 17. de Villiers TJ, Hall JE, Pinkerton JV, Perez SC, Rees M, Yang C, Pierroz DD. Revised global  
13 consensus statement on menopausal hormone therapy. *Maturitas*. 2016;91:153-155.
- 14 18. Archer DF, Sturdee DW, Baber R, de Villiers TJ, Pines A, Freedman RR, Gompel A, Hickey M,  
15 Hunter MS, Lobo RA, Lumsden MA, MacLennan AH, Maki P, Palacios S, Shah D, Villaseca P,  
16 Warren M. Menopausal hot flashes and night sweats: where are we now? *Climacteric*.  
17 2011;14(5):515-528.
- 18 19. Depypere H, Lademacher C, Siddiqui E, Fraser GL. Fezolinetant in the treatment of vasomotor  
19 symptoms associated with menopause. *Expert Opin Investig Drugs*. 2021;30(7):681-694.
- 20 20. Krull AA, Larsen SA, Clifton DK, Neal-Perry G, Steiner RA. A Comprehensive Method To  
21 Quantify Adaptations by Male and Female Mice With Hot Flashes Induced by the Neurokinin B  
22 Receptor Agonist Senktide. *Endocrinology*. 2017;158(10):3259-3268.
- 23 21. Fraser GL, Lederman S, Waldbaum A, Kroll R, Santoro N, Lee M, Skillern L, Ramael S. A phase  
24 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3

- 1 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.  
2 *Menopause*. 2020;27(4):382-392.
- 3 22. Depypere H, Timmerman D, Donders G, Sieprath P, Ramael S, Combalbert J, Hoveyda HR,  
4 Fraser GL. Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3  
5 receptor antagonist: a phase 2a trial. *J Clin Endocrinol Metab*. 2019;104(12):5893-5905.
- 6 23. Fraser GL, Hoveyda HR, Clarke IJ, Ramaswamy S, Plant TM, Rose C, Millar RP. The NK3  
7 receptor antagonist ESN364 interrupts pulsatile LH secretion and moderates levels of ovarian  
8 hormones throughout the menstrual cycle. *Endocrinology*. 2015;156(11):4214-4225.
- 9 24. Santoro N, Waldbaum A, Lederman S, Kroll R, Fraser GL, Lademacher C, Skillern L, Young J,  
10 Ramael S. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported  
11 outcomes in postmenopausal women with vasomotor symptoms: results of a randomized,  
12 placebo-controlled, double-blind, dose-ranging study (VESTA). *Menopause*. 2020;27(12):1350-  
13 1356.
- 14 25. Center for Drug Evaluation and Research. Draft Guidance. Estrogen and estrogen/progestin drug  
15 products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms –  
16 recommendations for clinical evaluation. Vol 20212003.
- 17 26. Buysse DJ, Yu L, Moul DE, Germain A, Stover A, Dodds NE, Johnston KL, Shablesky-Cade  
18 MA, Pilkonis PA. Development and validation of patient-reported outcome measures for sleep  
19 disturbance and sleep-related impairments. *Sleep*. 2010;33(6):781-792.
- 20 27. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug  
21 Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER).  
22 Guidance for Industry. Drug-induced liver injury: premarketing clinical evaluation. Vol  
23 20212009.
- 24 28. Newton KM, Carpenter JS, Guthrie KA, Anderson GL, Caan B, Cohen LS, Ensrud KE, Freeman  
25 EW, Joffe H, Sternfeld B, Reed SD, Sherman S, Sammel MD, Kroenke K, Larson JC, Lacroix

- 1 AZ. Methods for the design of vasomotor symptom trials: the menopausal strategies: finding  
2 lasting answers to symptoms and health network. *Menopause*. 2014;21(1):45-58.
- 3 29. Lederman S, Shapiro M, Stute P, Lee M, Wang X, Neal-Perry G. Phase 3 Study of Fezolinetant  
4 for Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause [A132].  
5 *Obstetrics & Gynecology*: May 2022 - Volume 139 - Issue - p 39S. *Obstetrics & Gynecology*.  
6 2022;139:39S.
- 7 30. Thurston RC, Chang Y, Buysse DJ, Hall MH, Matthews KA. Hot flashes and awakenings among  
8 midlife women. *Sleep*. 2019;42(9):zsz131.
- 9 31. Valiensi SM, Belardo MA, Pilnik S, Izbizky G, Starvaggi AP, Castelo Branco C. Sleep quality  
10 and related factors in postmenopausal women. *Maturitas*. 2019;123:73-77.
- 11 32. English M, Stoykova B, Slota C, Doward L, Siddiqui E, Crawford R, DiBenedetti D. Qualitative  
12 study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS  
13 Sleep Disturbance and Sleep-Related Impairment measures for assessment of VMS impact on  
14 sleep. *J Patient Rep Outcomes*. 2021;5(1):37.
- 15 33. Riemma G, Schiattarella A, La Verde M, Zarobbi G, Garzon S, Cucinella G, Calagna G, Labriola  
16 D, De Franciscis P. Efficacy of low-dose paroxetine for the treatment of hot flashes in surgical  
17 and physiological postmenopausal women: systematic review and meta-analysis of randomized  
18 trials. *Medicina (Kaunas)*. 2019;55(9):554.
- 19 34. Medic G, Wille M, Hemels ME. Short- and long-term health consequences of sleep disruption.  
20 *Nat Sci Sleep*. 2017;9:151-161.
- 21 35. Lederman S, Shapiro CM M, Stute P, Lee M, Wang X, Neal-Perry G. Phase 3 study of  
22 fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with  
23 menopause. *Obstet Gynecol*. 2022;139:39S [A132].
- 24 36. Goodman NF, Cobin RH, Ginzburg SB, Katz IA, Woode DE, American Association of Clinical  
25 E. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice

- 1 for the diagnosis and treatment of menopause: executive summary of recommendations. *Endocr*  
2 *Pract.* 2011;17(6):949-954.
- 3 37. Miyazaki K, Kaneko M, Narukawa M. Factors associated with high placebo response in clinical  
4 studies of hot flashes: a meta-analysis. *Menopause.* 2021;29(2):239-246.
- 5 38. Freeman EW, Ensrud KE, Larson JC, Guthrie KA, Carpenter JS, Joffe H, Newton KM, Sternfeld  
6 B, LaCroix AZ. Placebo improvement in pharmacologic treatment of menopausal hot flashes:  
7 time course, duration, and predictors. *Psychosom Med.* 2015;77(2):167-175.
- 8 39. van Die MD, Teede HJ, Bone KM, Reece JE, Burger HG. Predictors of placebo response in a  
9 randomized, controlled trial of phytotherapy in menopause. *Menopause.* 2009;16(4):792-796.
- 10 40. US Food and Drug Administration. Draft guidance for industry: estrogen and estrogen/progestin  
11 drug products to treat vasomotor symptoms and vulvular and vaginal atrophy symptoms -  
12 recommendations for clinical evaluation. Vol 20222003.
- 13 41. Simon JA, Gaines T, LaGuardia KD, Extended-Release Oxybutynin Therapy for VMSSG.  
14 Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical  
15 trial. *Menopause.* 2016;23(11):1214-1221.
- 16 42. Simon JA, Portman DJ, Kaunitz AM, Mekonnen H, Kazempour K, Bhaskar S, Lippman J. Low-  
17 dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials.  
18 *Menopause.* 2013;20(10):1027-1035.



1 **Figure Legends**

2 **Figure 1.** Study flow chart.

3 <sup>a</sup> Vasomotor symptoms data collected using an electronic VMS diary. Minimum average of 7  
4 moderate to severe VMS/day for 10 days before randomization.

5

6 **Figure 2.** Flow diagram.

7

8 **Figure 3.** Mean (A) frequency and (B) severity of moderate and severe VMS during the 52-week  
9 treatment period (FAS and FAS-fezolinetant exposure).

10 FAS, full analysis set; VMS, vasomotor symptoms.

11

12 **Figure 4.** (A) Distribution of the Patient Global Impression of Change in Sleep Disturbance at week  
13 12 and (B) the Patient Global Impression of Severity in Sleep Disturbance at week 12 (full analysis  
14 set).

15 NA, not applicable.

16

17 **Figure 5.** Percentage reduction in frequency of moderate and severe VMS per 24 hours by week  
18 (FAS).

19 FAS, full analysis set; VMS, vasomotor symptoms.

20

21

22

1 **Tables**2 **Table 1.** Inclusion and exclusion criteria

Inclusion criteria	Exclusion criteria
Born female, aged $\geq 40$ years and $\leq 65$ years at screening	Receiving strong or moderate cytochrome P450 1A2 (CYP1A2) inhibitors, hormone replacement therapy, hormonal contraceptive, or any treatment for VMS (prescription, OTC, or herbal)
BMI $\geq 18$ kg/m <sup>2</sup> and $\leq 38$ kg/m <sup>2</sup>	Previous/current history of a malignant tumor, except for basal cell carcinoma
Seeking treatment/relief for VMS associated with menopause and at the screening visit having: Spontaneous amenorrhea for $\geq 12$ consecutive months; Spontaneous amenorrhea for $\geq 6$ months with biochemical criteria of menopause (FSH $> 40$ IU/L); or Had bilateral oophorectomy $\geq 6$ weeks prior to the screening visit	SBP $\geq 130$ mm Hg or DBP $\geq 80$ mm Hg based on an average of 2–3 readings on at least 2 different occasions within the screening period)  Women who did not meet these criteria may, at the discretion of the investigator, be reassessed after initiation or review of antihypertensive measures  Women with a medical history of hypertension could be enrolled at the discretion of the investigator once they are medically clear (stable and compliant)
Within 10 days prior to randomization, must have a minimum average of 7–8 moderate-to-severe VMS/day, or 50–60/week	History within the last 6 months of undiagnosed uterine bleeding
Normal/negative or no clinically significant findings on mammogram within the previous 12 months or at screening	A medical condition or chronic disease (including history of neurological, hepatic, renal, CV, GI, pulmonary [eg, moderate asthma], endocrine or gynecological disease) or malignancy that could confound interpretation of the study
Normal or not clinically significant Pap test result within the previous 12 months or at screening	Active liver disease, jaundice, or elevated liver aminotransferases (ALT or AST), elevated total or direct bilirubin, elevated INR, or elevated alkaline phosphatase. Participants with mildly elevated ALT or AST up to $1.5 \times$ ULN could be enrolled if total and direct bilirubin were normal. Participants with mildly elevated alkaline phosphatase (up to $1.5 \times$ ULN) could be enrolled if cholestatic liver disease was

	excluded and no cause other than fatty liver was diagnosed. Participants with Gilbert's syndrome with elevated total bilirubin could be enrolled as long as direct bilirubin, hemoglobin, and reticulocytes were normal
Willing to undergo a transvaginal ultrasound to evaluate the uterus and ovaries at screening and at week 52 (EOT), and at early discontinuation for women who withdraw from the study prior to completion	Creatinine $>1.5 \times \text{ULN}$ ; or estimated glomerular filtration rate $\leq 59 \text{ mL/min per } 1.73 \text{ m}^2$ at screening
Willing to undergo an endometrial biopsy at screening and at week 52 (EOT) unless she has had a supracervical or full hysterectomy. The endometrial biopsy obtained at screening must be considered evaluable. In addition, willing to undergo endometrial biopsy in the event of uterine bleeding or early discontinuation of the study or study drug.	

1 ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CV,  
2 cardiovascular; CYP1A2, cytochrome P450 1A2; DBP, diastolic blood pressure; EOT, end of treatment;  
3 FSH, follicle-stimulating hormone; GI, gastrointestinal; INR, international normalized ratio; OTC, over  
4 the counter; Pap, Papanicolaou; SBP, systolic blood pressure; ULN, upper limit of normal; VMS,  
5 vasomotor symptoms.

6  
7  
8

1 **Table 2.** Key participant demographics and baseline characteristics

12-Week double-blind period (SAF) <sup>a</sup>					
Parameter	Placebo (n = 167)	Fezolinetant 30 mg (n = 166)	Fezolinetant 45 mg (n = 167)	Total (N = 500)	
Ethnicity, No. (%)					
Not Hispanic or Latina	134 (80.7)	132 (79.5)	126 (75.4)	392 (78.6)	
Hispanic or Latina	32 (19.3)	34 (20.5)	41 (24.6)	107 (21.4)	
Missing	1	0	0	1	
Race, No. (%)					
American Indian or Alaska Native	0	0	1 (0.6)	1 (0.2)	
Black or African American	31 (18.6)	35 (21.1)	33 (19.8)	99 (19.8)	
Korean	1 (0.6)	0	0	1 (0.2)	
> 1 race	1 (0.6)	0	1 (0.6)	2 (0.4)	
White	134 (80.2)	131 (78.9)	132 (79.0)	397 (79.4)	
Age, mean (SD), y	54.7 (4.6)	53.9 (4.9)	54.3 (5.4)	54.3 (5.0)	
Weight, mean (range), kg	74.57 (46.2- 125.0)	75.33 (48.0- 108.4)	74.62 (45.0- 107.4)	74.84 (45.0- 125.0)	
BMI, mean (range), kg/m <sup>2</sup>	28.16 (18.6- 38.0)	27.94 (18.1- 37.6)	27.91 (18.0- 37.5)	28.00 (18.0- 38.0)	
Current smoker, No. (%)	35 (21.0)	34 (20.5)	34 (20.4)	103 (20.6)	
Time since onset of VMS, mean (range), mo	81.9 (3-364)	76.2 (3-370)	81.7 (2-396)	80.0 (2-396)	
Amenorrhea, No. (%)					
No	8 (4.8)	3 (1.8)	5 (3.0)	16 (3.2)	
Yes	159 (95.2)	163 (98.2)	162 (97.0)	484 (96.8)	
Hysterectomy, No. (%)					
No	116 (69.5)	113 (68.1)	111 (66.5)	340 (68.0)	
Yes	51 (30.5)	53 (31.9)	56 (33.5)	160 (32.0)	
Oophorectomy, No. (%)					
No	130 (77.8)	132 (79.5)	129 (77.2)	391 (78.2)	
Yes	37 (22.2)	34 (20.5)	38 (22.8)	109 (21.8)	
Start of fezolinetant treatment (Safety analysis set-fezolinetant exposure) <sup>b</sup>					
Parameter	Fezolinetant 30 mg (n = 166)	Fezolinetant 45 mg (n = 167)	Placebo/ Fezolinetant 30 mg (n = 76)	Placebo/ Fezolinetant 45 mg (n = 75)	Total (n = 484)
Ethnicity, No. (%)					
Not Hispanic or Latina	132 (79.5)	126 (75.4)	62 (81.6)	58 (78.4)	378 (78.3)
Hispanic or Latina	34 (20.5)	41 (24.6)	14 (18.4)	16 (21.6)	105 (21.7)
Missing	0	0	0	1	1
Race, No. (%)					

American Indian or Alaska Native	0	1 (0.6)	0	0	1 (0.2)
Black/African American	35 (21.1)	33 (19.8)	11 (14.5)	18 (24.0)	97 (20.0)
Korean	0	0	1 (1.3)	0	1 (0.2)
> 1 race	0	1 (0.6)	1 (1.3)	0	2 (0.4)
White	131 (78.9)	132 (79.0)	63 (82.9)	57 (76.0)	383 (79.1)
Age, mean (SD), y	53.9 (4.9)	54.3 (5.4)	54.3 (4.2)	55.3 (4.9)	54.3 (5.0)
Weight, mean (range), kg	75.33 (48.0-108.4)	74.62 (45.0-107.4)	75.84 (48.8-112.0)	74.0 (46.2-125.0)	74.96 (45.0-125.0)
BMI, mean (range), kg/m <sup>2</sup>	27.94 (18.1-37.6)	27.91 (18.0-37.5)	28.70 (20.0-38.0)	27.87 (18.6-37.9)	28.04 (18.0-38.0)
Current smoker, No. (%)	34 (20.5)	34 (20.4)	15 (19.7)	14 (18.7)	97 (20.0)
Time since onset of VMS, mean (range), mo	76.2 (3-370)	81.7 (2-396)	73.4 (5-308)	98.2 (3-364)	81.1 (2-396)
Amenorrhea, No. (%)					
No	3 (1.8)	5 (3.0)	5 (6.6)	3 (4.0)	16 (3.3)
Yes	163 (98.2)	162 (97.0)	71 (93.4)	72 (96.0)	468 (96.7)
Hysterectomy, No. (%)					
No	113 (68.1)	111 (66.5)	51 (67.1)	52 (69.3)	327 (67.6)
Yes	53 (31.9)	56 (33.5)	25 (32.9)	23 (30.7)	157 (32.4)
Oophorectomy, No. (%)					
No	132 (79.5)	129 (77.2)	57 (75.0)	59 (78.7)	377 (77.9)
Yes	34 (20.5)	38 (22.8)	19 (25.0)	16 (21.3)	107 (22.1)

1 BMI, body mass index; ; SAF, safety analysis set; VMS, vasomotor symptoms.

2 Data shown in terms of No. (%), unless otherwise stated.

3 <sup>a</sup>For the double-blind period, data were collected from the first dose of study drug until week 12.

4 <sup>b</sup>For the extension period, data were collected from the first dose of study drug until week 52 for the fezolinetant groups and from week 13 to week 52 for the placebo/fezolinetant groups.

6

1 **Table 3.** Change from baseline to weeks 4 and 12 in daily mean frequency and severity of moderate to  
 2 severe VMS (FAS)

Analysis visit	Statistic	Placebo (n = 167)	Fezolinetant 30 mg (n = 166)	Fezolinetant 45 mg (n = 167)	
<b>Frequency of daily moderate to severe VMS</b>					
Baseline	Daily mean (SD)	11.59 (5.02)	11.23 (4.88)	11.79 (8.26)	
Week 4	No.	151	155	155	
	Daily mean (SD)	8.08 (6.50)	5.79 (6.02)	5.67 (7.29)	
Week 12	Change from baseline, LS mean (SE)	-3.72 (0.33)	-5.53 (0.33)	-6.26 (0.33)	
	LS mean (SE) difference vs placebo	-	-1.82 (0.46)	-2.55 (0.46)	
	95% CI	-	-2.73, -0.91	-3.45, -1.64	
	Unadjusted <i>P</i> value	-	<.001	<.001	
	No.	140	133	145	
	Daily mean (SD)	6.73 (7.58)	4.80 (5.59)	4.49 (5.39)	
Week 12	Change from baseline, LS mean (SE)	-4.97 (0.39)	-6.83 (0.39)	-7.50 (0.39)	
	LS mean (SE) difference vs placebo	-	-1.86 (0.55)	-2.53 (0.55)	
	95% CI	-	-2.94, -0.78	-3.60, -1.46	
	Unadjusted <i>P</i> value	-	<.001	<.001	
	<b>Severity of daily moderate-to-severe VMS</b>				
	Baseline	No.	167	166	167
Week 4	Daily mean (SD)	2.41 (0.32)	2.44 (0.33)	2.41 (0.34)	
	No.	151	155	155	
Week 12	Daily mean (SD)	2.11 (0.56)	1.97 (0.65)	1.80 (0.74)	
	Change from baseline, LS mean (SE)	-0.32 (0.05)	-0.47 (0.05)	-0.61 (0.05)	
	LS mean (SE) difference vs placebo	-	-0.15 (0.06)	-0.29 (0.06)	
	95% CI	-	-0.27, -0.02	-0.41, -0.16	
	Unadjusted <i>P</i> value	-	.021	<.001	
	No.	140	133	145	
Week 12	Daily mean (SD)	1.95 (0.68)	1.84 (0.79)	1.66 (0.79)	
	Change from baseline, LS mean (SE)	-0.48 (0.06)	-0.64 (0.06)	-0.77 (0.06)	
	LS mean (SE) difference vs placebo	-	-0.16 (0.08)	-0.29 (0.08)	
	95% CI	-	-0.33, 0.00	-0.45, -0.13	
	Unadjusted <i>P</i> value	-	<.05	<.001	

3  
 4 FAS, full analysis set; LS, least squares; VMS, vasomotor symptoms.

5

1 **Table 4.** Change from baseline in PROMIS SD SF 8b total score

2

12-Week double-blind period (FAS) <sup>a</sup>					
Analysis visit	Statistics	Placebo (n = 167)	Fezolinetant 30 mg (n = 166)	Fezolinetant 45 mg (n = 167)	
Baseline	No.	166	165	167	
	Mean (SD)	27.4 (7.0)	27.3 (6.6)	26.2 (6.6)	
Week 4	No.	151	155 <sup>b</sup>	158	
	Mean (SD)	24.5 (7.6)	23.4 (7.3)	21.3 (6.8)	
	LS mean change from baseline, mean (SE)	-2.6 (0.5)	-3.9 (0.5)	-5.3 (0.5)	
		-	-1.30 (0.7)	-2.7 (0.7)	
	LS mean difference vs placebo (SE)	-	0.082	<0.001	
	P-value vs placebo <sup>c</sup>	-	-	-	
Week 12	No.	144 <sup>d</sup>	139	145	
	Mean (SD)	23.8 (7.0)	23.0 (7.7)	21.2 (5.7)	
	LS mean change from baseline, mean (SE)	-3.4 (0.5)	-4.1 (0.5)	-5.5 (0.5)	
		-	-0.7 (0.7)	-2.0 (0.7)	
	LS mean difference vs placebo (SE)	-	0.381	0.007	
	P-value vs placebo <sup>c</sup>	-	-	-	
Start of fezolinetant treatment (Safety analysis set-fezolinetant exposure) <sup>e</sup>					
Analysis visit (duration of fezolinetant exposure)	Statistic	Fezolinetant 30 mg (n = 166)	Fezolinetant 45 mg (n = 167)	Placebo/ fezolinetant 30 mg (n = 76)	Placebo/ fezolinetant 45 mg (n = 75)
Baseline	No.	166	167	76	74
	Mean (SD)	27.4 (6.7)	26.2 (6.6)	27.2 (7.4)	27.6 (6.5)
Week 12 (0 weeks exposure for placebo switchers)	No.	145	149	f	f
	Mean (SD)	23.3 (7.7)	21.2 (5.7)		
	Change from Baseline, mean (SD)	-4.4 (8.1)	-4.7 (6.8)		
Week 24 (12 weeks exposure)	No.	134	138	67	69

for placebo switchers)

Mean (SD)	21.9 (7.0)	21.3 (7.3)	20.8 (6.7)	22.5 (7.0)
Change from Baseline, mean (SD)	-5.6 (7.3)	-4.7 (7.6)	-6.7 (7.4)	-4.8 (7.9)

Week 52 (40 weeks exposure for placebo switchers)

No.	107	116	55	54
Mean (SD)	21.2 (6.9)	20.2 (7.1)	20.5 (7.1)	22.1 (7.1)
Change from baseline, mean (SD)	-6.3 (7.3)	-5.7 (7.9)	-7.6 (8.4)	-4.8 (7.1)

1 BL, baseline; FAS, full analysis set; PROMIS SD SF 8b, Patient-reported Outcomes Measurement  
2 Information System Sleep Disturbance – Short Form 8b.

3 <sup>a</sup>For the double-blind period, data were collected from the first dose of study drug until week 12.

4 <sup>b</sup>n = 154 for LS change from baseline.

5 <sup>c</sup>Two-sided unadjusted *P*-value

6 <sup>d</sup>n = 143 for LS change from baseline.

7 <sup>e</sup>For the extension period, data were collected from the first dose of study drug until week 52 for the  
8 fezolinetant groups and from week 13 to week 52 for the placebo/fezolinetant groups.

9 <sup>f</sup>Exposure to fezolinetant began at Week 12.

10



1 **Table 5.** Change from baseline in MENQOL total score<sup>a</sup> during the 12-week double-blind period (FAS)  
 2  
 3

Analysis visit	Statistics	Placebo (n = 167)	Fezolinetant 30 mg (n = 166)	Fezolinetant 45 mg (n = 167)
Baseline	No.	165	165	167
	Mean (SD)	4.40 (1.35)	4.49 (1.34)	4.31 (1.31)
Week 4	No.	151 <sup>b</sup>	155 <sup>c</sup>	158
	Mean (SD)	3.62 (1.39)	3.30 (1.42)	3.01 (1.34)
	LS mean change from baseline, mean (SE)	−0.75 (0.10)	−1.17 (0.10)	−1.34 (0.09)
	LS mean difference vs placebo (SE)	—	−0.42 (0.14)	−0.59 (0.14)
	<i>P</i> value vs placebo <sup>d</sup>	—	0.002	<0.001
Week 12	No.	144 <sup>e</sup>	139	145
	Mean (SD)	3.43 (1.44)	3.22 (1.43)	2.92 (1.33)
	LS mean change from baseline, mean (SE)	−0.95 (0.10)	−1.18 (0.10)	−1.43 (0.10)
	LS mean difference vs placebo (SE)	—	−0.23 (0.15)	−0.47 (0.15)
	<i>P</i> value vs placebo <sup>d</sup>	—	0.122	0.001

4 FAS, full analysis set; LS, least squares; MENQOL, Menopause-Specific Quality of Life.

5 <sup>a</sup>Comprises all 4 domains and 29 items. A negative change indicates an improvement from baseline.

6 <sup>b</sup>n=150 for LS change from baseline.

7 <sup>c</sup>n = 154 for LS change from baseline.

8 <sup>d</sup>Mixed model repeated measurements analysis of covariance model with change from baseline as the  
 9 dependent variable and treatment group, week and smoking status (current vs former/never) as factors,  
 10 with baseline measurement and baseline weight as covariates, as well as an interaction of treatment by  
 11 week and an interaction of baseline measurement by week.

12 <sup>e</sup>n = 142 for LS change from baseline.

1 **Table 6.** Overview of AEs

12-Week double-blind period (SAF) <sup>a</sup>				
TEAE, No. (%)	Placebo (n = 167)	Fezolinetant 30 mg (n = 166)	Fezolinetant 45 mg (n = 167)	
TEAE	54 (32.3)	67 (40.4)	60 (35.9)	
Drug-related TEAE	11 (6.6)	24 (14.5)	25 (15.0)	
Serious TEAE	0	3 (1.8) <sup>b</sup>	2 (1.2) <sup>c</sup>	
Drug-related serious TEAE	0	0	0	
TEAE leading to permanent discontinuation of study drug	1 (0.6) <sup>d</sup>	2 (1.2) <sup>e</sup>	5 (3.0) <sup>f</sup>	
Drug-related TEAE leading to permanent discontinuation of study drug	0	1 (0.6)	5 (3.0)	
Deaths	0	0	0	
TEAEs by PT ( $\geq 2.0\%$ for any group)				
Upper respiratory tract infection	7 (4.2)	5 (3.0)	5 (3.0)	
Headache	4 (2.4)	5 (3.0)	6 (3.6)	
Dry mouth	0	4 (2.4)	4 (2.4)	
Arthralgia	1 (0.6)	5 (3.0)	1 (0.6)	
Diarrhea	4 (2.4)	1 (0.6)	2 (1.2)	
Nasopharyngitis	4 (2.4)	3 (1.8)	0	
Nausea	0	3 (1.8)	4 (2.4)	
Weight increased	1 (0.6)	5 (3.0)	1 (0.6)	
TEAEs of special interest				
Depression	4 (2.4)	3 (1.8)	1 (0.6)	
Liver test elevations	0	2 (1.2)	3 (1.8)	
Wakefulness	1 (0.6)	3 (1.8)	1 (0.6)	
Uterine bleeding	1 (0.6)	1 (0.6)	1 (0.6)	
Bone fractures	1 (0.6)	1 (0.6)	0	
Thrombocytopenia	0	2 (1.2)	0	
Potential abuse liability	1 (0.6)	0	0	
Endometrial hyperplasia/cancer or disordered proliferative endometrium	0	0	0	
Effect on memory	0	0	0	
Start of fezolinetant treatment (Safety analysis set-fezolinetant exposure) <sup>g</sup>				
TEAE, No. (%)	Fezolinetant 30 mg (n = 166)	Fezolinetant 45 mg (n = 167)	Placebo/ Fezolinetant 30 mg (n = 76)	Placebo/ Fezolinetant 45 mg (n = 75)
TEAE	107 (64.5)	106 (63.5)	43 (56.6)	45 (60.0)
Drug-related TEAE	33 (19.9)	30 (18.0)	8 (10.5)	8 (10.7)
Serious TEAE	9 (5.4)	8 (4.8)	2 (2.6)	4 (5.3)

Drug-related serious TEAE	0	1 (0.6)	0	1 (1.3)
TEAE leading to permanent discontinuation of study drug	4 (2.4)	7 (4.2)	2 (2.6)	3 (4.0)
Drug-related TEAE leading to permanent discontinuation of study drug	1 (0.6)	6 (3.6)	1 (1.3)	2 (2.7)
Deaths	0	0	0	1 (1.3)
TEAEs by PT ( $\geq 4.0\%$ for any group)				
COVID-19	9 (5.4)	15 (9.0)	4 (5.3)	3 (4.0)
Headache	8 (4.8)	12 (7.2)	1 (1.3)	4 (5.3)
Arthralgia	7 (4.2)	4 (2.4)	3 (3.9)	2 (2.7)
Back pain	5 (3.0)	6 (3.6)	2 (2.6)	3 (4.0)
Upper respiratory tract infection	7 (4.2)	8 (4.8)	1 (1.3)	0
Hot flush	3 (1.8)	7 (4.2)	4 (5.3)	0
Hypertension	5 (3.0)	7 (4.2)	1 (1.3)	0
Blood creatine phosphokinase increased	2 (1.2)	3 (1.8)	1 (1.3)	5 (6.7)
Weight increased	8 (4.8)	2 (1.2)	1 (1.3)	0
Pain in extremity	3 (1.8)	1 (0.6)	1 (1.3)	3 (4.0)
Ear infection	0	3 (1.8)	1 (1.3)	3 (4.0)
Gastroesophageal reflux disease	2 (1.2)	2 (1.2)	0	3 (4.0)
Anxiety	1 (0.6)	0	0	3 (4.0)
TEAEs of special interest				
COVID-19	9 (5.4)	16 (9.6)	4 (5.3)	4 (5.3)
Liver test elevations	4 (2.4)	9 (5.4)	1 (1.3)	1 (1.3)
Uterine bleeding	6 (3.6)	4 (2.4)	0	0
Depression	3 (1.8)	2 (1.2)	0	1 (1.3)
Wakefulness	3 (1.8)	2 (1.2)	0	0
Bone Fractures	2 (1.2)	1 (0.6)	0	1 (1.3)
Endometrial hyperplasia/cancer or disordered proliferative endometrium	1 (0.6)	0	1 (1.3)	1 (1.3)
Thrombocytopenia	2 (1.2)	0	0	0
Effect on memory	0	0	1 (1.3)	0
Potential abuse liability	0	0	0	0

1 AE, adverse event; PT, preferred term; TEAE, treatment-emergent adverse event.

2 Data shown for the safety analysis set (randomized participants who took  $\geq 1$  dose of study drug). In the  
3 double-blind period, 4 participants had confirmed and suspected cases of COVID-19 (1 receiving  
4 placebo, 2 receiving fezolinetant 30 mg, and 1 receiving fezolinetant 45 mg).

5 <sup>a</sup>For the double-blind period, data were collected from the first dose of study drug until week 12.

6 <sup>b</sup>Atrial fibrillation in 1 participant, tooth infection in 1 participant, and COVID-19 in 1 participant.

7 <sup>c</sup>Biliary dyskinesia in 1 participant and posterior tibial nerve injury in 1 participant.

8 <sup>d</sup>Increased appetite and hot flash in 1 participant.

9 <sup>e</sup>Fatigue and oropharyngeal pain in 1 participant and alexithymia in 1 participant.

10 <sup>f</sup>Arthralgia in 1 participant; abdominal pain, hemochezia, nausea, vomiting, and colitis in 1 participant;  
11 international normalized ratio increased in 1 participant; nausea in 1 participant; and alanine  
12 aminotransferase increased in 1 participant.

1 <sup>§</sup>For the extension period, data were collected from the first dose of study drug until week 52 for the  
2 fezolinetant groups and from week 13 to week 52 for the placebo/fezolinetant groups.  
3 A serious TEAE is a TEAE that, in the view of the investigator or sponsor, results in death, is life-  
4 threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability  
5 to conduct normal life functions, results in congenital anomaly/birth defect, requires inpatient  
6 hospitalization, results in discontinuation due to increases in liver enzymes, results in other medically  
7 important events.

ACCEPTED MANUSCRIPT

1 **Table 7.** Liver safety assessments  
 2

12-Week double-blind period (SAF) <sup>a</sup>				
Category, n/N (%) <sup>b</sup>	Placebo (n = 167)	Fezolinetant 30 mg (n = 166)	Fezolinetant 45 mg (n = 167)	
<b>ALT</b>				
> 3 times ULN	1/161 (0.6)	2/164 (1.2)	3/164 (1.8)	
> 5 times ULN	0/161	1/164 (0.6)	0/164	
> 8 times ULN	0/161	0/164	0/164	
<b>AST</b>				
> 3 times ULN	1/161 (0.6)	1/164 (0.6)	0/164	
> 5 times ULN	0/161	0/164	0/164	
<b>ALT or AST</b>				
ALT or AST > 3xULN	1/161 (0.6)	2/164 (1.2)	3/164 (1.8)	
ALT or AST > 5xULN	0/161	1/164 (0.6)	0/164	
ALT or AST > 8xULN	0/161	0/164	0/164	
<b>ALP</b>				
> 1.5 times ULN	4/162 (2.5)	0/164	1/164 (0.6)	
<b>Total bilirubin</b>				
> 2 times ULN	0/161	0/161	0/161	
ALT or AST > 3 times ULN and bilirubin > 2 times ULN	0/161	0/161	0/161	
ALT or AST > 3 times ULN, ALP < 2 times ULN, and bilirubin > 2 times ULN	0/161	0/161	0/161	
Start of fezolinetant treatment (Safety analysis set-fezolinetant exposure) <sup>c</sup>				
Category, n/N (%) <sup>b</sup>	Fezolinetant 30 mg (n = 166)	Fezolinetant 45 mg (n = 167)	Placebo/ Fezolinetant 30 mg (n = 76)	Placebo/ Fezolinetant 45 mg (n = 75)
<b>ALT</b>				
> 3xULN	3/164 (1.8)	6/164 (3.7)	0/76	2/74 (2.7)
> 5xULN	1/164 (0.6)	1/164 (0.6)	0/76	0/74
> 8xULN	0/164	0/164	0/76	0/74
<b>AST</b>				
> 3xULN	1/164 (0.6)	2/164 (1.2)	0/76	0/74
> 5xULN	0/164	0/164	0/76	0/74
<b>ALT or AST</b>				
ALT or AST > 3xULN	3/164 (1.8)	7/164 (4.3)	0/76	2/74 (2.7)
ALT or AST > 5xULN	1/164 (0.6)	1/164 (0.6)	0/76	0/74
ALT or AST > 8xULN	0/164	0/164	0/76	0/74
<b>ALP</b>				
> 1.5xULN	3/164 (1.8)	2/164 (1.2)	3/76 (3.9)	3/74 (4.1)
<b>Total bilirubin</b>				

> 2xULN	0/164	0/164	0/76	0/74
(ALT or AST > 3xULN) and bilirubin > 2xULN	0/164	0/164	0/76	0/74
(ALT or AST > 3xULN) and ALP < 2xULN and bilirubin > 2xULN	0/164	0/164	0/76	0/74

1 ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper  
2 limit of normal.


3 Data shown for the safety analysis set (randomized participants who took  $\geq 1$  dose of study drug; a  
4 participant receiving a treatment different from their randomized treatment was assigned to the treatment  
5 group received as first dose). A participant could be counted in multiple categories as they were included  
6 in all that apply (eg, if a participant had a level > 8 x ULN they were also included in the > 3 x and > 5 x  
7 ULN categories). The denominator is the number of participants who had at least one non-missing value  
8 during the 12-week double-blind treatment period.

9 <sup>a</sup>For the double-blind period, data were collected from the first dose of study drug until week 12.

10 <sup>b</sup>Others were analyzed but are not included due to no events.


11 <sup>c</sup>For the extension period, data were collected from the first dose of study drug until week 52 for the  
12 fezolinetant groups and from week 13 to week 52 for the placebo/fezolinetant groups.

13  
14



**Figure 1**  
147x62 mm ( x DPI)


1  
2  
3  
4



**Figure 2**  
147x131 mm ( x DPI)


1  
2  
3  
4







**Figure 3**  
100x159 mm ( x DPI)

1  
2  
3  
4



**Figure 4**  
147x139 mm ( x DPI)

1  
2  
3  
4



**Figure 5**  
147x67 mm ( x DPI)

1  
2  
3